Refine
Year of publication
Document Type
- Article (31209)
- Part of Periodical (11958)
- Book (8284)
- Doctoral Thesis (5729)
- Part of a Book (3967)
- Working Paper (3389)
- Review (2939)
- Contribution to a Periodical (2369)
- Preprint (2181)
- Report (1561)
Language
- German (43255)
- English (29530)
- French (1071)
- Portuguese (843)
- Multiple languages (320)
- Spanish (309)
- Croatian (302)
- Italian (198)
- mis (174)
- Turkish (168)
Keywords
- Deutsch (1082)
- Literatur (873)
- taxonomy (766)
- Deutschland (553)
- Rezension (511)
- new species (452)
- Rezeption (354)
- Frankfurt <Main> / Universität (341)
- Übersetzung (329)
- Geschichte (301)
Institute
- Medizin (7726)
- Präsidium (5193)
- Physik (4516)
- Extern (2742)
- Wirtschaftswissenschaften (2710)
- Gesellschaftswissenschaften (2374)
- Biowissenschaften (2187)
- Biochemie und Chemie (1978)
- Frankfurt Institute for Advanced Studies (FIAS) (1770)
- Center for Financial Studies (CFS) (1632)
Die Weltschmerzorganisation (IASP) definiert Schmerz als "ein unangenehmes Sinnes- und Gefühlserlebnis", das als 'drückend', 'scheußlich', 'heiß' oder als '7' auf einer Skala dargestellt werden kann. Er lässt sich als erhöhte neuronale Aktivität beschreiben und kann mittels bildgebender Verfahren in spezifischen Hirnarealen 'sichtbar' gemacht werden. Und doch bleibt der Schmerz ein rein subjektiv erlebtes Phänomen, das sich strikten Messungen entzieht. Wann also wird ein Reiz zum Schmerz? Der Vortrag spürt der Wandlungsfähigkeit des Schmerzerlebens anhand von Beispielen aus Wissenschaft, Kultur und Geschichte nach.
Disruption of the blood-air barrier, which is formed by lung microvascular endothelial and alveolar epithelial cells, is a hallmark of acute lung injury. It was shown that alveolar epithelial cells release an unidentified soluble factor that enhances the barrier function of lung microvascular endothelial cells. In this study we reveal that primarily prostaglandin (PG) E2 accounts for this endothelial barrier-promoting activity. Conditioned media from alveolar epithelial cells (primary ATI-like cells) collected from BALB/c mice and A549 cells increased the electrical resistance of pulmonary human microvascular endothelial cells, respectively. This effect was reversed by pretreating alveolar epithelial cells with a cyclooxygenase-2 inhibitor or by blockade of EP4 receptors on endothelial cells, and in A549 cells also by blocking the sphingosine-1-phosphate1 receptor. Cyclooxygenase-2 was constitutively expressed in A549 cells and in primary ATI-like cells, and was upregulated by lipopolysaccharide treatment. This was accompanied by enhanced PGE2 secretion into conditioned media. Therefore, we conclude that epithelium-derived PGE2 is a key regulator of endothelial barrier integrity via EP4 receptors under physiologic and inflammatory conditions. Given that pharmacologic treatment options are still unavailable for diseases with compromised air-blood barrier, like acute lung injury, our data thus support the therapeutic potential of selective EP4 receptor agonists.
In order to promote the accessibility of biodiversity data in historic and contemporary literature, we introduce a new interdisciplinary project called BIOfid (FID=Fachinformationsdienst, a service for providing specialized information). The project aims at a mobilization of data available in print only by combining digitization of scientific biodiversity literature with the development of innovative text mining tools for complex, eventually semantic searches throughout the complete text corpus. A major prerequisite for the development of such search tools is the provision of sophisticated anatomy ontologies on the one hand, and of complete lists of species names (currently considered valid as well as all synonyms) at a global scale on the other hand. In the initial stage, we chose examples from German publications of the past 250 years dealing with the geographic distribution and ecology of vascular plants (Tracheophyta), birds (Aves), as well as moths and butterflies (Lepidoptera) in Germany. These taxa have been prioritized according to current demands of German research groups (about 50 sites) aiming at analyses and modeling of distribution patterns and their changes through time. In the long term, we aim at providing data and open source software applicable for any taxon and geographic region. For this purpose, a platform for open access journals for long-term availability of professional e-journals will be established. All generated data will also be made accessible through GFBio (German Federation for Biological Data). BIOfid is supported by the LIS-Scientific Library Services and Information Systems program of the German Research Foundation (DFG).
Background: Red blood cell (RBC) depletion is a standard graft manipulation technique for ABO-incompatible bone marrow (BM) transplants. The BM processing module for Spectra Optia, “BMC”, was previously introduced. We here report the largest series to date of routine quality data after performing 50 clinical-scale RBC-depletions.
Methods: Fifty successive RBC-depletions from autologous (n = 5) and allogeneic (n = 45) BM transplants were performed with the Spectra Optia BMC apheresis suite. Product quality was assessed before and after processing for volume, RBC and leukocyte content; RBC-depletion and stem cell (CD34+ cells) recovery was calculated there from. Clinical engraftment data were collected from 26/45 allogeneic recipients.
Results: Median RBC removal was 98.2% (range 90.8–99.1%), median CD34+ cell recovery was 93.6%, minimum recovery being 72%, total product volume was reduced to 7.5% (range 4.7–23.0%). Products engrafted with expected probability and kinetics. Performance indicators were stable over time.
Discussion: Spectra Optia BMC is a robust and efficient technology for RBC-depletion and volume reduction of BM, providing near-complete RBC removal and excellent CD34+ cell recovery.
A high proportion of patients with breast cancer develop bone metastases, yet data on routine treatment with bone-targeted agents (BTA) are rare. We report real-life outcome data of patients with breast cancer metastasised to the bone treated by office-based oncologists in Germany.
The ongoing, prospective, multicentre, population-based cohort study Tumour Registry Breast Cancer (TMK) was started in 2007 in 140 centres across Germany.
This interim analysis of 1094 patients with bone metastases revealed differences among the tumour subtypes: at start of first-line therapy, 36% of the patients with hormone receptor (HR)-positive and only 20% of the patients with HR-negative tumours presented with bone-only metastasis. The majority of patients with bone metastases (89%, n = 976) received BTA therapy. In 2014–2015, 37% of the patients received the bisphosphonate zoledronic acid and 36% the antibody denosumab. Median duration of BTA therapy was 20 months (interquartile range 31.5 months), starting a median of 3 weeks after diagnosis of bone metastases, and ending a median of 7 weeks before death. The median overall survival (OS) also varied among the types of metastasis at start of first-line therapy ranging from 54 months (95% confidence interval [CI] 37.6–70.8), 38 months (95% CI 29.4–44.2) to 28 months (95% CI 24.2–31.0) for patients with bone-only metastases, non-visceral with or without bone metastases and visceral with or without bone metastases respectively.
We show that choice and duration of BTA therapies are in conformity with guidelines applicable in Germany. To our knowledge, this is the first presentation of data on incidence, metastatic pattern, treatment and survival of patients with bone metastases in routine practice.
IFLS-Journal. Nr. 22, 2017
(2017)
Background: Infections with the hepatitis C virus (HCV) are a global public health problem. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. Newly introduced direct acting antivirals, especially interferon-free regimens, have improved rates of sustained viral response above 90% in most patient groups and allow treating patients who were ineligible for treatment in the past. These new regimens have replaced former treatment and are recommended by current guidelines. However, there is an ongoing discussion on high pharmaceutical prices. Our aim was to assess the long-term cost-effectiveness of treating hepatitis C genotype 1 patients with sofosbuvir/ledipasvir (SOF/LDV) treatment in Germany.
Material and Methods: We used a Markov cohort model to simulate disease progression and assess cost-effectiveness. The model calculates lifetime costs and outcomes (quality-adjusted life years, QALYs) of SOF/LDV and other strategies. Patients were stratified by treatment status (treatment-naive and treatment-experienced) and absence/presence of cirrhosis. Different treatment strategies were compared to prior standard of care. Sensitivity analyses were performed to evaluate model robustness.
Results: Base-case analyses results show that in treatment-naive non-cirrhotic patients treatment with SOF/LDV dominates the prior standard of care (is more effective and less costly). In cirrhotic patients an incremental cost-effectiveness ratio (ICER) of 3,383 €/QALY was estimated. In treatment-experienced patients ICERs were 26,426 €/QALY and 1,397 €/QALY for treatment-naive and treatment-experienced patients, respectively. Robustness of results was confirmed in sensitivity analyses.
Conclusions: Our analysis shows that treatment with SOF/LDV is cost-effective compared to prior standard of care in all patient groups considering international costs per QALY thresholds.
GOeTHEO : Ausgabe 16
(2017)
Bromodomain-containing protein 4 (BRD4) is a member of the bromo- and extraterminal (BET) domain-containing family of epigenetic readers which is under intensive investigation as a target for anti-tumor therapy. BRD4 plays a central role in promoting the expression of select subsets of genes including many driven by oncogenic transcription factors and signaling pathways. However, the role of BRD4 and the effects of BET inhibitors in non-transformed cells remain mostly unclear. We demonstrate that BRD4 is required for the maintenance of a basal epithelial phenotype by regulating the expression of epithelial-specific genes including TP63 and Grainy Head-like transcription factor-3 (GRHL3) in non-transformed basal-like mammary epithelial cells. Moreover, BRD4 occupancy correlates with enhancer activity and enhancer RNA (eRNA) transcription. Motif analyses of cell context-specific BRD4-enriched regions predicted the involvement of FOXO transcription factors. Consistently, activation of FOXO1 function via inhibition of EGFR-AKT signaling promoted the expression of TP63 and GRHL3. Moreover, activation of Src kinase signaling and FOXO1 inhibition decreased the expression of FOXO/BRD4 target genes. Together, our findings support a function for BRD4 in promoting basal mammary cell epithelial differentiation, at least in part, by regulating FOXO factor function on enhancers to activate TP63 and GRHL3 expression.